sutetinib (SZMD4) / Jiangsu Suzhong Pharma, Medolution, Teligene - LARVOL DELTA

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=99 | Recruiting | Sponsor: Teligene US | Trial completion date: Feb 2025 ➔ Jun 2026 | Trial primary completion date: Aug 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Teligene US | Trial completion date: Sep 2025 ➔ Apr 2026 | Trial primary completion date: Sep 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=99 | Recruiting | Sponsor: Teligene US | Phase classification: P2b ➔ P2

Metastases • Phase classification • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects. (PubMed, Invest New Drugs) - "The registration No. is CTR20201933, and the date of registration is 2020-10-16)."

Journal • PK/PD data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Teligene US | Trial completion date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Jun 2025 ➔ Sep 2025

Metastases • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Teligene US

Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Teligene US | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (clinicaltrials.gov) - P2 | N=66 | Not yet recruiting | Sponsor: Teligene US

Metastases • New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations. (ASCO 2023) - "Sutetinib demonstrated a high response rate with durable antitumor activity in patients with NSCLC harboring uncommon EGFR mutations. The toxicities are expected and comparable to other EGFR TKIs. A multi-center phase 2b study is ongoing in the United States and China to further evaluate Sutetinib in uncommon EGFR mutation NSCLC."

Clinical • Metastases • P2a data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

"We have an AMAZING line-up of @UCSFPCCMFellows fellows & faculty at #ATS2023: Sunday sessions: Drs. @nthakurMD @KByanova @_schraufnagel_ @nestocasillas @Adali_Mtz @SZMD84 @LungTxptMD! And I'll be presenting a #MedEd seminar w/ Drs @SKassutto @basakcoruhUW @GrahamCarlos too!" (@LekshmiMD)

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - P2b | N=99 | Recruiting | Sponsor: Teligene US | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2024 ➔ Feb 2025 | Trial primary completion date: Feb 2023 ➔ Aug 2024

Enrollment open • Metastases • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

"@KotasMaya @mwsharp5 @nvhstewart @Oh_HeyMan @parvskumar @NidaQadirMD @rebeccabermanmd @rupaljs @SarahGoglinMD @SAlbaNguyenMD @UrmimalaSarkar @FutureDocs @SZMD84 @carly_zapata7 & many more! So thankful for you all! 🙏🏿♥️" (@LekshmiMD)